Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Amortization of Deferred Charges (2019 - 2024)

Fennec Pharmaceuticals (FENC) has disclosed Amortization of Deferred Charges for 6 consecutive years, with -$1.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Amortization of Deferred Charges fell 2012.73% year-over-year to -$1.1 million, compared with a TTM value of $52000.0 through Dec 2024, down 76.47%, and an annual FY2024 reading of $52000.0, down 76.47% over the prior year.
  • Amortization of Deferred Charges was -$1.1 million for Q4 2024 at Fennec Pharmaceuticals, down from $301000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $405000.0 in Q2 2024 and bottomed at -$1.1 million in Q4 2024.
  • Average Amortization of Deferred Charges over 5 years is $50133.3, with a median of $53000.0 recorded in 2023.
  • The sharpest move saw Amortization of Deferred Charges surged 1988.24% in 2020, then crashed 2012.73% in 2024.
  • Year by year, Amortization of Deferred Charges stood at $355000.0 in 2020, then plummeted by 97.75% to $8000.0 in 2021, then surged by 587.5% to $55000.0 in 2022, then changed by 0.0% to $55000.0 in 2023, then plummeted by 2012.73% to -$1.1 million in 2024.
  • Business Quant data shows Amortization of Deferred Charges for FENC at -$1.1 million in Q4 2024, $301000.0 in Q3 2024, and $405000.0 in Q2 2024.